Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

236.22
+6.923.02%
Post-market: 236.480.2586+0.11%19:58 EDT
Volume:1.91M
Turnover:449.27M
Market Cap:31.52B
PE:42.04
High:238.97
Open:228.88
Low:228.34
Close:229.30
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.16
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.28
PE(LYR):101.38

Loading ...

Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Dow Jones
·
Jul 16

Alnylam Schedules Conference Call on Second-quarter 2026 Results

Reuters
·
Jul 16

Alnylam Initiates Phase 2 Trial of Mivelsiran in Down Syndrome-associated Alzheimer’s Disease

Reuters
·
Jul 15

Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says

MT Newswires Live
·
Jul 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)

TIPRANKS
·
Jul 14

BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating

MT Newswires Live
·
Jul 14

Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 13

Movement Alert|Alnylam Pharmaceuticals Falls 5.29% in Regular Trading, Trading at $281.53

Market Focus
·
Jul 13

Alnylam price target lowered to $410 from $505 at Truist

TIPRANKS
·
Jul 13

Alnylam Pharmaceuticals Inc : Truist Securities Cuts Target Price to $410 from $505

THOMSON REUTERS
·
Jul 13

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-07-10

Reuters
·
Jul 11

Movement Alert|Alnylam Pharmaceuticals Falls 5.08% in Regular Trading, Trading at $296.89

Market Focus
·
Jul 11

Alnylam Pharmaceuticals is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Simply Wall St.
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)

TIPRANKS
·
Jul 10

Alnylam, Bridgebio Gain from Astrazeneca-ionis Drug Missing Target

Dow Jones
·
Jul 10

Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating

MT Newswires Live
·
Jul 09

AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis

TradingKey
·
Jul 09

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-07-09

Reuters
·
Jul 09